


TRANSITION FROM PHENOBARBITONE TO PEXION® (imepitoin)

Prepared by the global Canine Epilepsy Advisory Group: Sigitas Cizinauskas, Robyn Farquhar, Gualtiero Gandini, Jacques Penderis, Kai Rentmeister, Jean Laurent Thibaud, Sandra Tyler, Holger Volk

Transition from phenobarbitone to PEXION®



* See PEXION® Dose Adjustment Protocol.

† If seizure frequency or severity increases during dose reduction, return to previous dose and maintain combination therapy.

‡ Rate of dose adjustment may change according to clinical status of patient.

§ Consider the potential of withdrawal seizures.

Development of
PEXION® protocol
sponsored by ...



See product label for full claim details and directions for use. Boehringer Ingelheim Animal Health New Zealand Limited, Level 3, 2 Osterley Way, Auckland, New Zealand. Pexion® is a registered trademark of Boehringer Ingelheim Vetmedica Inc. Registered pursuant to the ACVM Act 1997 | ACVM Nos. A010986 & A010987 | Restricted Veterinary Medicine. Available only under a veterinary authorisation. © Copyright 2023 Boehringer Ingelheim Animal Health New Zealand Limited. All rights reserved.
For further information relating to transition, dose adjustment and treatment protocols, please contact our Veterinary Medical Services team on 0800 822 800. NZ-CAN-0036-2023

Pexion®
For *all* the reasons.